Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of SMARCB1 loss in bladder cancer tumor growth and metastasis.

ABSTRACT: To investigate the loss of SMARCB1 , a critical component of SWI/SNF complex in bladder cancer tumorigenesis and metastasis. We investigated the loss by generating SMARCB1 KO cells by CRISPR and rescuing the expression of SMARCB1 by lentivirus in the KO cell line. The cell lines were implanted orthotopically into bladder wall to investigate its effects on tumor growth and metastatic phenotype.

ORGANISM(S): Homo sapiens

PROVIDER: GSE212762 | GEO | 2023/11/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptional response to Smarcb1 re-expression in murine derived Smarcb1 deficient p53 null tumors

Project description:SMARCB1 (Snf5/Ini1/Baf47) is a potent tumor suppressor, the loss of which serves as the diagnostic feature in Malignant Rhabdoid Tumors (MRT) and Atypical Teratoid/Rhabdoid Tumors (AT/RT), two highly aggressive forms of pediatric neoplasms. Here, we restore Smarcb1 expression in cells derived from Smarcb1-deficient tumors which developed in Smarcb1-heterozygous p53-/- mice. Profiling Smarcb1 dependent gene expression we find genes which are dependent on Smarcb1 expression to be enriched for ECM and cell adhesion functions. We identify Igfbp7, which is related to the insulin-like growth factor binding proteins family, as a downstream target of Smarcb1 transcriptional activity, and show that re-introduction of Igfbp7 alone can hinder tumor development. Two cancer cell lines, 167 and 365, derived from Smarcb1-deficient tumors which developed in Smarcb1-heterozygous p53-/- mice were re-infected with a retro-viral vector for Smarcb1 re-expression or an empty retro-viral vector as control. Total-RNA was collected 3 days post infection so as to enrich for direct targets of Smarcb1 transcriptionaly regulated genes

2013-12-31 | E-GEOD-46017 | biostudies-arrayexpress

Gene expression analysis of human haploid cells (HAP1) depleted of SMARCB1 and SMARCA4

Project description:The aim of this study is to analyze the change in genome wide expression levels in HAP1 cells upon loss of SMARCB1, SMARCA4 or both these genes together. The SMARCB1 and SMARCA4 genes were the hits from a genome wide screen involving genetrap mutagenesis to find new players that are involved in sensitivity to Doxorubicin (Dox). It was found that loss of SMARCB1 and SMARCA4 genes impart resistance in HAP1 cells to Dox. To validate this, the genes were knocked out in HAP1 cells with CRISPR-Cas9 technology. Gene expression levels in SMARCB1 null, SMARCA4 null and SMARCB1-SMARCA4 double null cells were compared to wildtype HAP1 cells using RNAseq. From these experiments it was found that SMARCB1 loss caused several fold increase in ABCB1 gene levels. ABCB1 is an efflux pump in cells responsible for flushing out many small-molecule drugs. Further analysis of this gene confirmed that ABCB1 was the main factor responsible for Dox resistance upon SMARCB1 loss. In total there are four different cell types with two replicates for each cell type. Therefore, 8 samples in total.

2016-08-22 | E-GEOD-75515 | biostudies-arrayexpress

Analysis of the role of SMARCB1 in bladder cancer cell line T24 [ATAC-seq]

Project description:To identify DNA accessibility targets regulated by the SWI/SNF subunit SMARCB1 in bladder cancer, we compared the ATAC-seq signals in T24 cells engineered for SMARCB1 knockout, non-targeting control, or SMARCB1 re-expression following knockout. Analysis of altered DNA accessibility profiles revealed new roles for SMARCB1 in the regulation of gene expression in bladder cancer, and suggested new therapeutic opportunities.

2023-11-17 | GSE213964 | GEO

Expression profiling following SMARCB1 re-expression in MRT cell lines time course over 14 days

Project description:MRT cell lines KD, SWOH, LM, DEV and G401 were expression profiled following SMARCB1 re-expression using a lentivirus. Samples were taken at Day 0,1,3,7 and 14 and compared to empty vector control experiments.

2024-12-31 | E-MTAB-6674 | biostudies-arrayexpress

Glutathione-S-transferase theta 2 (GSTT2) modulates the tumor microenvironment and the response to BCG immunotherapy in a murine orthotopic model of bladder cancer

Project description:Whilst M. bovis Bacillus Calmette-Guérin (BCG) therapy remains the gold-standard for treatment of high-risk non-muscle invasive bladder cancer (BC), 30-40% of patients fail therapy, resulting in disease recurrence and progression. Loss of glutathione-S-transferase theta 2 (GSTT2) expression has been associated with improved response to fewer instillations of BCG. To understand these responses, wild-type (WT) and GSTT2-knockout (KO) mice were implanted orthotopically with MB49-PSA BC cells, and mice were treated with four weekly BCG instillations, after which the bladders were harvested for single-cell RNA sequencing.

2024-12-11 | GSE281932 | GEO

Effect of SMARCB1 loss in bladder cancer tumor growth and metastasis.

Project description:Effect of SMARCB1 loss in bladder cancer tumor growth and metastasis.

| PRJNA877222 | ENA

Transcriptional response to Smarcb1 re-expression in murine derived Smarcb1 deficient p53 null tumors

2013-12-31 | GSE46017 | GEO

Genome wide expression analysis of mouse xenograft tissues derived from urothelial cancer cell UM-UC3 orthotopic recycling

Project description:Urothelial cancer cells UM-UC3 was orthotopically implanted in mouse bladder wall and then recycled for multiple cycles. Spontaneous tumor tissues including primaries, lymph node metastasis, distant metastasis (lung and bone) and circulating tumor cells (CTCs) were collected and the mRNA expression profiling was examed by microarray

2017-05-22 | GSE48496 | GEO

A quality control factor for chromatin complexes is synthetic lethal in SMARCB1-mutant cancers

Project description:While oncogenes can potentially be inhibited with small molecules, the loss of tumor suppressors is more common and is problematic because the tumor suppressor proteins are no longer present to be targeted. Notable examples include SMARCB1-mutant cancers, which are highly lethal malignancies driven by the inactivation of a subunit of SWI/SNF chromatin remodeling complexes. To generate mechanistic insight into the consequences of SMARCB1 mutation and to identify vulnerabilities, we contributed 14 SMARCB1-mutant cell lines to a near genome-wide CRISPR screen as part of the Cancer Dependency Map Project1-3. Here, we report that the little-studied gene DDB1-CUL4 Associated Factor 5 (DCAF5) is required for the survival of SMARCB1-mutant cancers. We show that DCAF5 serves a quality control function for SWI/SNF complexes and promotes degradation of incompletely assembled SWI/SNF complexes in the absence of SMARCB1. Upon depletion of DCAF5, SMARCB1-deficient SWI/SNF complexes re-accumulate, bind to target loci, and restore SWI/SNF-mediated gene expression to levels sufficient to reverse the cancer state, including in vivo. Consequently, cancer results not from the loss of SMARCB1 function per se but rather from DCAF5-mediated degradation of SWI/SNF complexes. These data indicate that therapeutic targeting of ubiquitin-mediated quality control factors may effectively reverse the malignant state of some cancers driven by disruption of tumor suppressor complexes.

2024-01-21 | PXD046273 | Pride

A quality control factor for chromatin complexes is synthetic lethal in SMARCB1-mutant cancers

2024-01-21 | PXD046275 | Pride